SEOUL (Reuters) -South Korean drug maker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies, to help allay customer concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback